Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Mozhgan Dorkhan

Mozhgan Dorkhan

Specialist physician

Mozhgan Dorkhan

Glycemic and non-glycemic effects of pioglitazone in triple oral therapy in patients with type 2 diabetes mellitus

Author

  • M Dorkhan
  • Martin Magnusson
  • A Frid
  • A Grubb
  • L Groop
  • S Jovinge

Summary, in English

OBJECTIVES: To examine pioglitazone as add-on to metformin and insulin secretagogues in patients with type 2 diabetes and inadequate glycaemic control and its effect on glycaemic control, surrogate measures of insulin sensitivity (adiponectin) and beta-cell function (proinsulin/insulin) and fluid retention.

DESIGN AND SETTING: Prospective open-label study of 54 patients with type 2 diabetes and HbA1c>or=6.5% admitted to outpatient unit at Malmö University Hospital. The patients received 30-45 mg pioglitazone daily during 26 weeks in addition to their existing antidiabetic medication. After 26 weeks, one-third of patients were followed for 3 months without pioglitazone.

RESULTS: HbA1c decreased (7.8+/-0.9-6.3+/-0.9%, P<0.001) with 61% of patients achieving levels<6.5%. However, in the group followed for another 3 months HbA1c increased (6.1+/-0.73-7.1+/-0.9, n=18, P<0.001) after pioglitazone withdrawal. Adiponectin increased (6.1+/-2.8-13.2+/-5.8 microg mL-1, P<0.001) and the proinsulin to insulin ratio decreased (0.89+/-0.66-0.66+/-0.53, P<0.001). Nt-proBNP increased from 487.3+/-252.2 to 657.8+/-392.1 pmol L-1 (P<0.001).

CONCLUSIONS: Pioglitazone is effective in achieving glycaemic targets and reducing risk factors involved in atherosclerosis and improving beta-cell function when used as part of triple oral therapy in patients with type 2 diabetes and secondary drug failure. Nt-proBNP increase with concomitant decrease in haemoglobin suggests a subclinical sign of fluid retention.

Department/s

  • Genomics, Diabetes and Endocrinology
  • Cardiovascular Research - Hypertension
  • Department of Clinical Sciences, Malmö
  • Division of Clinical Chemistry and Pharmacology
  • Stem Cell Center

Publishing year

2006-08

Language

English

Pages

125-133

Publication/Series

Journal of Internal Medicine

Volume

260

Issue

2

Document type

Journal article

Publisher

Wiley-Blackwell

Topic

  • Cardiac and Cardiovascular Systems
  • Medicinal Chemistry
  • Endocrinology and Diabetes

Keywords

  • Adiponectin
  • Administration, Oral
  • Aged
  • Biomarkers
  • Blood Glucose
  • Case-Control Studies
  • Cystatin C
  • Cystatins
  • Diabetes Mellitus, Type 2
  • Drug Therapy, Combination
  • Female
  • Glyburide
  • Hemoglobin A, Glycosylated
  • Humans
  • Hypoglycemic Agents
  • Insulin
  • Male
  • Metformin
  • Middle Aged
  • Natriuretic Peptide, Brain
  • Peptide Fragments
  • Proinsulin
  • Prospective Studies
  • Statistics, Nonparametric
  • Thiazolidinediones
  • Comparative Study
  • Journal Article
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

Status

Published

Research group

  • Genomics, Diabetes and Endocrinology
  • Cardiovascular Research - Hypertension

ISBN/ISSN/Other

  • ISSN: 1365-2796